instructor bios · opportunities certificate instructors. ajay bhatia is a commercial leader ......

PHARMA CHALLENGES &OPPORTUNITIES CERTIFICATE

INSTRUCTOR BIOS

Cynthia Ban is the current Global Head of Regulatory CMC for Vaccines at Sanofi Pasteur. She is an accomplished Senior Global Leader in the pharmaceutical industry

specializing in Regulatory Affairs with experience in Corporate Compliance.

During her career she has led teams across multiple geographies and a wide range of therapeutic areas (Vaccines, Oncology, HIV, Specialty Care, Rare diseases) and has extensive experience in new and rapidly changing environments such as pandemics. Cynthia is a graduate of UTM.

CynthiaBan

PHARMA CHALLENGES &OPPORTUNITIES CERTIFICATE INSTRUCTORS

Jordan Berman is Vice-President, Global Corporate Affairs, Business Transformation and Strategic Planning at Apotex. In this role, he is responsible for developing and

communicating the organization’s narrative to a wide variety of stakeholders. His broad focus is to protect and strengthen the Apotex reputation, drive employee engagement and build alignment with the company strategy. Jordan is also accountable for the short and long term strategic planning for Apotex, as well as enterprise strategic initiatives focused on transforming the company’s operations.

Prior to Apotex, Jordan held dual corporate communications and strategy roles for 10 years. This included a Global Communications Leadership role supporting the Executive Chairman for Johnson & Johnson’s medical devices business, a $25 billion organization with 55,000 employees worldwide, as well as many years at AstraZeneca Canada as head of Business Planning & Risk Management.

Jordan holds a joint Master of Business Administration from the Kellogg School of Management and the Schulich School of Business and is a frequent speaker on a range of topics. He is the author of the forthcoming book, The Trust Trifecta: A Leader’s Guide to Gaining Trust.

JordanBerman


Ajay Bhatia is a Commercial Leader with over 17 years of experience in the Canadian Pharmaceutical Industry. Ajay started his career at Johnson & Johnson in 2003 as a sales

representative and quickly progressed into roles of increasing responsibility. In 2009 Ajay joined GSK in their Leadership Development Program where he held various positions in the Commercial Division including Market Access, Marketing and Sales Management where he led a team of 8 individuals in the GTA.

In 2018 Ajay joined Astellas where he has led the successful launch of a new Oncology Franchise at the company. Ajay has experience in various therapeutic areas including Primary Care, Vaccines, Dermatology, Biologics and Oncology. He has won a number of Canadian and Global Industry awards and enjoys speaking at major Industry conferences.

Ajay holds an Hon. BSc from the University of Toronto and an MBA in Strategic Marketing from McMaster University.

AjayBhatia


Currently the President at KJC Consulting, Dr. Canning has over twenty years of leadership and business management experience in the pharmaceutical and biotechnology

sector. He has expertise in technology assessment, basic research and genetics, research alliances/scouting, clinical research, statistics, epidemiology, data management, medical development, commercial assessment, medical affairs, outsourcing and contracts, strategy and operations, venture capital, and international corporate development.

Prior to starting his own consulting business, Dr. Canning held senior positions at GSK (Canada and China), MaRS Innovation (now known as Toronto Innovation Acceleration Partners (TIAP)), and The Green Organic Dutchman (TGOD).

Dr. Canning did postdoctoral work at the University of Alabama at Birmingham (Supervisor: Dr. Mike Wyss), and at the University of Toronto (Supervisors: Drs. Bev Orser and John F. MacDonald). Dr. Canning holds a Ph.D. in Physiology (Supervisor: Dr. LS Leung) from Western University. He holds an M.B.A. from the Ivey Business School, Western University and was recognized as an Ivey Scholar in this program.

KevinCanning


Dr. Rafael Chiuzi is an experienced Organizational Behaviour Consultant with a strong, demonstrated capacity to leverage human capital for the benefit of organizations and people

alike. In his ten plus years of innovative practice in North & South America, Europe and the Middle East, he has been able to overcome widespread organizational challenges, and successfully implement lasting and meaningful change.

Rafael is also a published author and Assistant Professor, Teaching Stream, at the University of Toronto Mississauga where he teaches organizational behaviour and related courses.

RafaelChiuzi


Dr. Dan Clow currently leads the Ethics and Compliance Team at GSK. Until the fall of 2018 he was Director, Public Policy and Advocacy where for eight years he led the team

responsible for health, industrial, pharmaceutical and biologics policy at the National and Federal levels.

He also oversaw the team serving as GSK’s point of contact for patient advocacy groups and professional organizations (including medical associations and societies) and served GSK in several key corporate governance roles.

Dan completed his undergraduate and graduate degrees at Queen’s University, graduating with his Ph.D. in Pharmacology and Toxicology in 1988. His neuroscience research interests led him to subsequently complete a post - doctoral fellowship in the Department of Anatomy at the University of Hawai’i at Manoa. Since joining GSK (formerly Glaxo Wellcome ) in 1996, Dan has held multiple roles in the Public Affairs, Market Access , Medical and now Ethics and Compliance Divisions.

DanClow


Chris Cummins started his career as a corporate commercial litigator at a top global law firm and joined GSK in September 2014 as legal counsel and has supported all areas of GSK’s

business. Chris served as Chief of Staff to GSK Canada’s GM and worked in all areas of Market Access as the Director of Pricing and Payer Solutions responsible for pricing governance and strategy as well as public/private payer negotiations and strategy. Chris has returned to his legal counsel role to support the integration of Pfizer and GSK’s consumer health businesses as part of the worldwide joint venture between the two companies.

ChrisCummins


Dorothy Czylyski has been working in healthcare & pharmaceutical marketing for 20 years.

With a Master of Science (MSc) in Clinical Pharmacology, she started her marketing communications career as a Medical Writer, moving into Account Management and Operations at healthcare agencies Medicus LifeBrands, SCRIPT, Klick Health, and most recently Fresh Squeezed Ideas, an Insights & Strategy firm where she was President.

In January 2019 Dorothy opened NFA Health in collaboration with No Fixed Address Inc., a fully integrated marketing agency. Dorothy has built an impressive portfolio over the course of her career, working with pharma clients across almost every therapeutic area, from insight & strategy development, regulatory expertise, sales rep materials, and Advisory Board meetings, to digital communications and media. Dorothy sits on the Board of Directors for the Ontario Pharmaceutical Marketing Association (OPMA) and is on multiple Advisory Committees at the Pharmaceutical Advertising Advisory Board (PAAB).

DorothyCzylyski


Dr. Colin Hall holds a Ph.D. in Enzymology / Biotechnology from McGill University. His areas of academic interest involved the purification, stabilization and

characterization of enzymes.

He began his professional career as a Lead Scientist and R & D Manager, tasked with the development of immuno-chromatographic assays for infectious diseases and human hormones. He has obtained Lead Auditor accreditations in ISO 13485 (medical devices), ISO 17025 (testing and calibration labs) and ISO 9001 (quality management).

In his current role of Director of Quality Assurance and Regulatory Affairs at Prollenium Medical Technologies, he coordinates the audit program and performs licensing activities, working with various agencies including Health Canada, FDA, European Notified Bodies, ANVISA and the TGA.

ColinHall


Duncan holds a Bachelor’s of Science (Chemistry and Biochemistry), a Master’s of Science (Biochemistry) and a Master’s of Business Administration all from the

University of Toronto. In addition, he is a Project Management Professional (PMP). For over 30 years, he has primarily worked with inventors in the Life Sciences, especially University professors assisting them in bringing their ideas to market. He has worked in a major pharmaceutical company, as a venture capitalist and with the technology transfer teams at each of Ontario’s Universities. He has lectured on and taught business and biotechnology at the high school, college and university levels. Duncan also manages Hexagon Innovating, a consulting firm focused on the fuzzy front end of new product development, sourcing and in-licensing technology, performing technology and intellectual property reviews, doing market research and competitive intelligence, developing business models and strategy, partnering, fundraising, as well as project and portfolio management.

Duncan bringing his commercial and industry experience to the classroom as well as his interest in pedagogy, especially as it relates to critical thinking and experiential learning. Over the last 2+ years, he has taught courses at UofT, including in the Master of Biotechology, and undergraduate courses for the IMI Business Minor and Human Biology (St George).

DuncanJones


Dr. Rav Kumar is Special Advisor to the Vice-President and Principal, University of Toronto Mississauga (UTM) with a focus on the future Centre for Medicinal Chemistry. He

is also a strategic advisor to several startup companies in the pharmaceutical and cannabinoid industries. Rav recently served as Managing Director of Apotex operations in India leading over 2,000 professionals in Pharmaceutical R&D, Manufacturing, Quality, Regulatory Affairs & Commercial Services.

Prior to Apotex, Dr. Kumar spent 25 years with GlaxoSmithKline in the UK, France and Canada at vice-president level leading R&D, Business Development and Commercial functions. He has been involved with development of numerous medicines and vaccines plus many successful business change initiatives.Dr. Kumar is passionate about growing Canadian Life Sciences and has been involved with many industry-academic-government collaborations. He conceived the $150M spinout of GSK’s vaccines R&D to create the Neomed Vaccines and Biologics Centre of Excellence in Montreal. For these contributions and numerous leadership roles on boards, non-profits and industry association work, he was recognized with the 2014 Award for Leadership in in Canadian Pharmaceutical Sciences.Rav has a Pharmacy Degree and completed a PhD in Novel Drug Delivery at University of Bath in the UK.

RavKumar


Dr. Timothy Lee has a Ph.D. in Biochemical Engineering. He then did a post-doctoral fellowship and eventually become a senior scientist at SANOFI where he was involved

in the optimization of biologics processes to improve product yield.

His area of expertise include bacterial and mammalian cell culture fermentation, primary protein recovery and column chromatography. Dr. Lee has also worked as a biopharmaceutical consultant for the NIH, DARPA and Department of Defense (DoD) on government funded projects.

He then moved to Allergan, California where he served as Director of Research and Development formulating Botox for different medical indications such as Osteoarthritis, reticular back pain and migraine.

He is currently the Director of R&D at Prollenium Medical Technologies working on new Hyaluronic Acid formulations and bead technologies to bring the dermal products to market. He has also published several patents & well established peer-reviewed journals and presented extensively globally over the last several years, outlining the work performed in the industry.

TimothyLee


Lisa Mullett is General Manager of Sunovion Pharmaceuticals Canada Inc., a subsidiary of Sunovion Pharmaceuticals Inc., a global biopharmaceutical company focused

on the innovative application of science and medicine to help people with serious medical conditions. She guides the organization’s overall business strategy in Canada and leads the cross-functional team responsible for driving the growth of products in the Canada market portfolio.

Ms. Mullett has over 25 years of pharmaceutical industry experience including senior leadership roles in Canadian, U.S. and global markets spanning sales and marketing, strategy and planning, government affairs, business development and new product planning across multiple therapeutic areas. Ms. Mullett holds a Bachelor of Arts degree in Administrative and Commercial Studies from the University of Western Ontario.

LisaMullett


Dr. Leigh Revers has more than 15 years of experience working in the life sciences sector, both in academia and industry.

Trained as a chemist and molecular biologist in the Dyson Perrins Laboratory, he came to Canada in 1996 as the recipient of a Leverhulme Scholarship to work with Prof. Harry Schachter on developmental enzymes involved in human diseases at Toronto’s Hospital for Sick Children. His research interests in complex carbohydrates as mediators of events at the cell-surface led to his interest in cancer. He joined Dr Jean Gariépy’s research team in 1999 to work on novel toxins capable of exploiting cancer-related carbohydrate signals. A long-held interest in entrepreneurship led in 2000 to his becoming a co-founder of Molecular Templates Inc. (MTI), an private biotech company focussed on the development of novel toxin-based cancer therapeutics.

In May 2006, he was appointed Assistant Director with the MBiotech Programme at the University of Toronto. In 2007, Dr. Revers co-founded a consulting practice, AdamsRevers, which provides specialist scientific and financial services to SMEs in the life sciences. Dr. Revers holds Bachelor’s, Master’s and Doctoral degrees in Physical Sciences from University of Oxford.

LeighRevers


instructor bios · opportunities certificate instructors. ajay bhatia is a commercial leader ......

Documents